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Abstract
Background: In a cancer cell the number of copies of a locus may vary due to amplification and deletion and
these variations are denoted as copy number alterations (CNAs). We focus on the disparity of CNAs in tumour
samples, which were compared to those in blood in order to identify the directional loss of heterozygosity.
Methods: We propose a numerical algorithm and apply it to data from the Illumina 109K-SNP array on 112
samples from breast cancer patients. B-allele frequency (BAF) and log R ratio (LRR) of Illumina were used to
estimate Euclidian distances. For each locus, we compared genotypes in blood and tumour for subset of samples
being heterozygous in blood. We identified loci showing preferential disparity from heterozygous toward either the
A/B-allele homozygous (allelic disparity). The chi-squared and Cochran-Armitage trend tests were used to examine
whether there is an association between high levels of disparity in single nucleotide polymorphisms (SNPs) and
molecular, clinical and tumour-related parameters. To identify pathways and network functions over-represented
within the resulting gene sets, we used Ingenuity Pathway Analysis (IPA).
Results: To identify loci with a high level of disparity, we selected SNPs 1) with a substantial degree of disparity
and 2) with substantial frequency (at least 50% of the samples heterozygous for the respective locus). We report
the overall difference in disparity in high-grade tumours compared to low-grade tumours (p-value < 0.001) and
significant associations between disparity in multiple single loci and clinical parameters. The most significantly
associated network functions within the genes represented in the loci of disparity were identified, including lipid
metabolism, small-molecule biochemistry, and nervous system development and function. No evidence for over-
representation of directional disparity in a list of stem cell genes was obtained, however genes appeared to be
more often altered by deletion than by amplification.
Conclusions: Our data suggest that directional loss and amplification exist in breast cancer. These are highly
associated with grade, which may indicate that they are enforced with increasing number of cell divisions.
Whether there is selective pressure for some loci to be preferentially amplified or deleted remains to be confirmed.
Background
Higher organisms such as humans are diploid, which
means that all chromosomes except the sex chromo-
somes are present in two copies (2 n). During DNA
replication, unique genomic segments of original DNA
are normally copied just one time, but in specific situa-
tions, these fragments are either not replicated entirely
o rt h e ya r ec o p i e dm o r et h a no n c e .T h ev a r i a t i o n
between normal and actual copy number of a DNA seg-
ment is referred to as copy number differences, which
in normal cells are referred to as copy number varia-
tions (CNVs) and in tumour cells as copy number
alternations (CNAs) [1]. Such chromosomal variations
have been associated with genetic disorders (for CNVs)
and the progression of cancer (for CNAs) [2]. The size
of CNVs in normal tissues is often shorter than CNAs
in tumour tissues, which can cover a large region of the
human genome (Mb) [3]. Array-based comparative
genomic hybridization (CGH) is used for detection of
CNVs and CNAs [4,5].
Recently, new techniques have been developed to
s t u d yC N V sa n dC N A sa tah i g h e rr e s o l u t i o nu s i n g
high-density arrays of single nucleotide polymorphisms
(SNPs) [6]. SNPs are variations in the single-base locus
of the genome within members of a species or paired
chromosomes of an individual. In general, SNPs have
precise positions on the chromosome and two alleles
(maternal and paternal), and SNP-based arrays are
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mal aberrations and loss of heterozygocity (LOH) status
[7]. Recent advances in the systematic study of genomic
alterations in human cancer samples have made it possi-
ble to understand this disease better and identify key
genes with underlying roles in oncogenesis [8]. In the
present study, we describe the development of a numer-
ical algorithm based on Euclidian distances to extract
the maximum level of information from SNP array data
in blood-tumour pairs, with regard to both chromoso-
mal aberrations and loss of heterozygosity. We apply the
a l g o r i t h mt oI l l u m i n a1 0 9 KS N Pa r r a yd a t aa n ds h o w
how it can be used to mine information on a single-
SNP, cytogenic region as well as in gene lists and at the
pathway level. We focus on the disparity of CNAs in
tumour samples, which were compared to those in
blood in order to identify the directional loss of
heterozygosity.
Methods
Materials
The 112 samples used here are a subset of a larger
patient series consisting of 920 samples, which were col-
lected from breast cancer patients to study the effect of
disseminating tumour cells to the blood and bone mar-
row [9]. The samples were collected at five different hos-
pitals in the Oslo region and have so far been extensively
studied on both the clinical and biological levels [9,10].
DNA isolation
Tumour tissues were snap-frozen at -80°C. Samples of
mononucleus peripheral blood cells were drawn in tubes
and centrifuged. Before freezing, the cell pellet was
resuspended to a concentration of 30 × 10
6 cells/ml in a
freezing solution containing RPMI added with 10%
DMSO and 20% FCS as well as Dnase. The samples
were then frozen at -70°C before being stored in liquid
nitrogen. Before DNA isolation, 240 μlP r o t . K( A B -
Applied Biosystems) and 400 μl 1 × PBS without CaMg
were added to the frozen samples on ice. The samples
were incubated at 55°C until thawed and then trans-
ferred after mixing to the vessels in the Applied Biosys-
tems 340A Nucleic Acid Extractor. The remaining
process of DNA isolation followed the standard proce-
dures for the extractor using a phenol-chloroform based
method. DNA from frozen tumour tissue was extracted
according to standard procedures of the Applied Biosys-
tems 340A Nucleic Acid Extractor.
All patients provided informed consent, and the study
was approved by the local regional ethical committees.
Genotyping
The genotyping used has been previously described [11],
and blood-tumour pairs were genotyped using the
Human-1 109K BeadChip array (Illumina, San Diego,
CA, USA). For each sample, the corresponding log R
ratio (LRR) and B allele frequency (BAF) were extracted
for both blood and tumour using the Illumina Beadstu-
dio Genotyping software, which is based on the transfor-
mation of two channels’ allelic intensity values [7].
Briefly Illumina’s Beadstudio software performs normali-
zation on the two raw allelic intensity values (X, Y)f o r
each locus (SNP). X and Y values are respectively
denoted as allele A and allele B. The normalized allele
intensities are transformed to total signal intensity, R (R
= X + Y), and relative allelic signal intensity ratio, theta
(θ =a r c t a n ( Y/X)(2/π)) [12].Illumina provides two sup-
plementary parameters, LRR and BAF,w h i c hr e f e rt o
the normalized and calibrated form of R and θ.B A F
represents the proportion of one SNP allele (B)t ot h e
total number of A and B alleles (NB/(NA + NB)) for each
given loci. The Illumina Infinium platform detects chro-
mosomal aberrations by comparing the normalized
intensity of a subject sample and a reference sample
using two modes of analysis: 1) a single-sample mode,
which derives reference values from canonical genotyp-
ing clusters (0, 0.5, 1) created from clustering on normal
reference samples; 2) Paired-sample mode, which makes
intensity (R) comparisons between a subject sample and
its paired reference sample. Genomic plots of LRR (LRR
=l o g 2(Rsubject/Rreference)) and BAF of the three canonical
clusters are used to detect chromosomal aberrations
[1,13,14]. Comparing custom-clustered data to HapMap-
clustered data, we observe improved scoring using cus-
tom clustering. The genotypes for both blood and
tumour were therefore extracted using custom cluster-
ing [15]. To improve the results of genotyping for those
samples that have not performed well, we used the cus-
tom-clustered data.
Missing values are denoted as NaN for both BAF and
LRR. Updated SNP information (position and gene asso-
ciation) was derived when available using the UCSC
Genome Browser (Human Mar. 2006 Assembly
(NCBI36/hg18)) [16], dbSNP (build 130), Ensembl gen-
ome browser (Ensembl genes 57 database on Homo
sapiens genes (GRCh37) dataset) [17], and CHIP Bioin-
formatics Tools, Goldenpath: hg18, dbSNP: build 130
[18].
Description of computational algorithm
Pre-processing of data
Traditional Array CGH provides information on CNAs
based on the Log R intensity ratios. The benefit of the
Illumina SNP array analysis is that it provides additional
information related to B allele frequency. The Beadstu-
dio software presents information, based on two allelic
intensity values, related to both Log R ratio and B allele
frequency. To analyze the Illumina output, we propose a
Kaveh et al. BMC Medical Genomics 2011, 4:85
http://www.biomedcentral.com/1755-8794/4/85
Page 2 of 13computational algorithm consisting of the following
steps for each chromosome (illustrated by the flowchart
in Additional file 1, Figure S1).
We denote bij and tij as the blood sample and tumour
sample, respectively. Here, i = 1,..., r and j = 1,..., c
represent the number of loci and the number of sam-
ples, where r = 109352 and c = 112. Figure 1 illustrates
the algorithm below for one locus. The Illumina data
were pre-processed by sorting BAF and LRR values by
chromosome and subsequently by position. All loci
residing on chromosome Y were removed from our cal-
culations. We denote BAF and LRR as × and y, respec-
t i v e l y .W eu s e dt h eb l o o dd a t aa sar e f e r e n c ea n d
assumed a threshold to divide it into three regions (AA,
AB, and BB). Monomorph loci and loci with less than
three distinct genotype groups were considered non-
informative and removed. The BAF value varies between
0 and 1 and the signal for the three genotypes on the x
axis clusters around (AA ~0 ,AB ~0 . 5 ,BB ~ 1); the
assumed threshold covers samples in the following
regions:
a. AA - homozygous: (0 ≤ bij ≤ 0.2)
b. AB - heterozygous: (0.2 < bij ≤ 0.8)
c. BB - homozygous: (0.8 < bij ≤ 1)
After filtering, we obtained 96,273 loci which modify
index j into j = 1,..., r’,w h e r er ’ is the total number of
loci without non-informative data.
Allelic disparity
In the horizontal direction, for each locus of Blood’,
we obtained mean (μBi =
1
n
n  
j=1
bij) and standard
deviation(SBi =
     
  1
n − 1
n  
j=1
(bij − μBi)
2). In the next
step, heterozygous blood samples were extracted and
labelled, as well as the entire tumour. To identify which
tumour samples shifted from the heterozygous toward
either one of the homozygous regions, we measured the
distance (D = xB -x T) of associated samples in both the
x and y axes, where D is the allelic disparity of Blood’
and Tumor’ samples. We deal only with those samples
where μBi − 2SBi < D <μ Bi +2 SBi . For each locus, the
frequencies of disparity of individuals were calculated.
Here, let n(tAAj) and n(tBBj)denote the numbers of sam-
ples for j shifted toward AA-a n dBB-h o m o z y g o u s ,
respectively. Based on the sample frequencies of each
SNP, we defined a score (S) denoting the propensity of
each SNP to lose either the B or A allele:
S =
⎧
⎪ ⎪ ⎨
⎪ ⎪ ⎩
1 −
n(tBBj)
n(tAAj)
.100 for n(tAAj) > n(tBBj)
1 −
n(tAAj)
n(tBBj)
.100 for n(tAAj) < n(tBBj)
(1)
We can apply and modify an arbitrary threshold via
Score (S).
Furthermore, since we identify the number of samples
shifted toward A or B-allele, we defined the percentage
of samples shifted toward minor allele (r(tBBj)), the per-
centage of samples shifted toward major allele (r(tAAj)),
and the percentage of heterozygous with disparity
(r(tABj)), where
LogR ratio(y) 
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Figure 1 Position of one blood sample in heterozygous. The allelic disparity, amplification or deletion of one paired sample (blood-tumour)
is illustrated in the heterozygous region. The position of one blood sample is denoted by (x1,y1) in the heterozygous region (AB). The same
sample in the tumour can be either unaltered or shifted toward minor allele (AA-homozygous-amplification (x3,y3), AA-homozygous-deletion (x4,
y4)), major allele (BB-homozygous-amplification (x2,y2) or BB-homozygous-deletion (x5,y5)). B-allele frequency is used for allelic disparity and Log R
ratio for amplification or deletion.
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n(tBBj)
n(tAAj)+n(tBBj)
.100 (2)
r(tAAj)=
n(tAAj)
n(tAAj)+n(tBBj)
.100 (3)
and
r(tABj)=
n(tAAj)+n(tBBj)
n(tABj)
.100 (4)
The percentage of allele-specific disparity is given by
 j = r(tBBj) − r(tAAj) (5)
Based on the genotypes in blood, we tested for each
SNP whether it fulfilled the criteria for Hardy-Weinberg
(HWE) equilibrium [19]. Given one degree of freedom
and a 0.95 confidence interval (CI), the threshold for the
chi-square value is 3.841. Values equal to or below this
threshold indicate that a locus is in HWE.
Pathway and network analysis
Ingenuity Pathway Analysis (IPA) [20] version 9.0
(Release Date: 2011-03-22), Content version: 3206
(Release Date: 2011-02-11)) was used to analyse selected
sets of genes in order to identify over-represented cano-
nical pathways and networks. IPA core analysis allows
us to find interactions between genes and proteins,
related networks, functions and canonical pathways in
the context of biological processes. The selected gene
list was uploaded into IPA. The only filter used for the
network analysis was “only consider molecules and/ or
relationships where species = Human”. The analysis
included both direct and indirect relationships as well as
endogenous chemicals, and for the network analysis the
maximum number of molecules allowed per network
was 140. In the network analysis, molecules of interest
which interact with other molecules in the Ingenuity
Knowledge Base are identified as Network Eligible mole-
cules and serve as “seeds” for generating networks. The
networks are scored with a numerical value. The score
is based on 1) the number of Network Eligible mole-
cules in the network, 2) size of the network, 3) Network
Eligible molecules in the given dataset, and 4) the num-
ber of molecules in the IPA database that could poten-
tially be included in the network. The network score is
the -log(Fisher’s Exact test result), which is based on the
hypergeometric distribution.N e t w o r kf u n c t i o nd i s p l a y s
the functional annotations associated with a specific net-
work. Top networks represent associated network func-
tions based on a score which reflects the negative
logarithm of the p-value, which aggregates the likelihood
of the genes in the network being found together due to
random chance. Score ≥ 2 was considered significant.
For the canonical pathways, the significance of the asso-
ciation between our defined data sets and the canonical
pathways are assessed in two ways by the software: 1)
the ratio of the number of molecules from our gene lists
that map to a given canonical pathway and 2) False Dis-
covery Rate (FDR) (Benjamini and Hochberg [21]) by the
negative logarithm of B-H p-values indicating the likeli-
hood that the association between the genes in our gene
sets and a specific canonical pathway are explained by
chance alone. Top biological functions were assigned to
each network by the negative logarithm of B-H p-value,
corrected for multiple testing (Source: IPA online
manual).
Chi-square test
The statistical chi-square test in R version 2.11.1 was
used to estimate the association between the observed
level of disparity and, among other, clinical and tumour-
related parameters (TP53 mutation, ER, PR, HER2,
Lymph node status, and subtypes of breast cancer).
Cochran-Armitage trend test
The Cochran-Armitage trend test [21] is applied in R
version 2.11.1 to detect the linear trend of ordered cate-
gorical data in a 2 × 3 contingency table. In this article,
we used the Cochran-Armitage trend test for clinical
parameters of grade and tumour size.
Detection of amplification and deletion
Based on the log R ratio, amplifications and deletions
were detected with the following procedure: 1) LRR for
tumour data were smoothed by the piecewise constant
function (PCF) algorithm [22,23];2) Obtained PCF values
were transformed into non-logarithmic values of
smoothed LRR; 3) Mean of samples per locus was calcu-
lated for the data obtained in 2) and a histogram of the
mean values was made (Figure 2); 4) To distinguish a
proper threshold for amplification, deletion and normal
region, three higher peaks were selected around 0.925, 1
and 1.12 in the non-logarithmic smoothed LRR; 5)
Based on these three peaks, ±0.07 (logarithmic value of
0.95 and 1.05) was chosen as the threshold, where >
0.07 was classified as amplification and -0.07 ≤ normal ≤
0.07 a nd < -0.07 as deletion (Figure 1).
Results
In a two-dimensional space, a point is distinguished by
two characters × and y; here, × is denoted by B allele fre-
quency and y by Log R ratio (Figure 1). The two-dimen-
sional position of one sample (x1,y1) in the heterozygous
region (AB) in the blood (blue circle) is compared to its
position in the tumour (red circle) to identify shifts toward
AA-homozygous-Amplification (x3,y3), AA-homozygous-
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Page 4 of 13Deletion (x4,y4), BB-homozygous-Amplification (x2,y2), or
BB-homozygous-Deletion (x5,y5). Horizontal shifting is
shown by vector-a (B allele frequency) and vertical with
vector-b (Log R ratio). By using the algorithm introduced
in the Methods (Description of computational algorithm)
on a dataset consisting of genotypes from 112 blood-
tumour paired samples collected from breast cancer
patients, we extracted information on changes in geno-
types (allelic loss, here denoted as allelic disparity). The
algorithm was applied separately to each autosomal chro-
mosome as well as the × chromosome. In all, 96,273 loci
were left after removing non-informative loci (see Meth-
ods on pre-processing of data) distributed across all chro-
mosomes. The number of loci per chromosome varied
between 1268 loci on chromosome 21 to 8559 on chromo-
some 1 (the numbers of SNPs and genes before and after
filtering are given in Table 1 for each chromosome).
Overall trends for allelic disparity in the genome
It is assumed that a locus has been subjected to allele-
specific disparity if the signal from a heterozygous geno-
type shifts toward one or the other homozygous geno-
type at a distance larger than two standard deviations of
the mean of the heterozygote for all samples. In order
to identify the loci with the highest levels of disparity,
we defined a score (S in eq. (1)) based on the sample
frequency of asymmetrical shift for each heterozygous
genotype, and all loci above or equal to 75 were selected
(see Methods on allelic disparity), leaving 13,198 loci
(Additional file 2, Figure S2). A full list of the 13,198
loci with information related to the genotypes in blood
(number of samples in each genotype, number of sam-
ples in homozygote for both minor and major alleles,
test for Hardy-Weinberg equilibrium, percent heterozyg-
osity, number of missing genotypes, minor allele fre-
quency, minor and major alleles) are given in Additional
file 3, Table S1 as well as the information regarding gen-
otypes in tumour (score (S), percentage and number of
disparity toward minor or major allele (in eq. 2 and 3,
respectively), percentage of heterozygote with disparity
in eq. (4), percentage of allele-specific disparity in eq.
(5) and preferential allele).
Chromosomal regions enriched for allelic disparity
In order to identify chromosomal regions with a high
degree of disparity, we grouped the 13,198 loci accord-
ing to cytoband localisation. The 13,198 loci fulfilling
the criteria of score 75 or higher were distributed on
778 cytobands with 1-77 loci per cytoband. The cyto-
bands having 30% and higher disparity are highlighted
in Figure 3 (Table 2). Severall o c ih a v eb e e np r e v i o u s l y
reported in association with breast cancer.
Single-SNP allelic disparity
To further identify loci with a high degree of disparity,
we looked at the single-SNP level (Additional file 3,
Table S1). For all SNPs, we counted the number of
alleles in our dataset and obtained the actual genotype.
A compelling example is the SNP rs325349 (A/G) on
chromosome 5 located in CDH9, for which 91.7 percent
Figure 2 Histogram of mean of samples per SNPs. Mean of all samples per locus in a non-logarithmic PCF’ed tumour dataset to identify the
proper threshold.
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in the tumour and all shift in one direction, toward the
major allele (A) (Figure 4 A and 4B). SNP rs543304
located in BRCA2 on chromosome 13 also showed a
high level of disparity, where 30 percent of the studied
samples were heterozygous with 26 percent displaying
disparity (n = 9), the majority toward the minor allele
( G ,n=8 )( F i g u r e4Ca n d4 D ) .A n o t h e re x a m p l ei s
rs4241189 located in HECW2 on chromosome 2, where
33 percent of the samples were heterozygous, 28 percent
(n = 11) showing disparity (primarily toward the minor
allele (G), n = 10) (Figure 4 E and 4F).
Allelic disparity in relation to clinical parameters
We observed significantly different frequencies of allelic
disparity events according to grade, from well differen-
tiated (G1) to poorly differentiated (G3) breast cancers
(p-value < 0.001 (Table 3)). Histologic grade is based on
the microscopic appearance of the cancer cells, which
are graded into four categories: Grades 1, 2, 3 and 4.
Grade 1 tumours are well-differentiated and resemble
normal cells; these tumours tend to grow slowly and are
considered less aggressive. Grade 2 tumours are moder-
ately differentiated, but grade 3 and 4 tumours tend to
differentiate poorly and grow rapidly [24]. Figure 5
shows the trend from well differentiated (G1) toward
poorly differentiated (G3) for the disparity level of
samples.
Allelic disparity was also found to be associated with
HER2, ER, PR and TP53 mutation status. A significant
higher level of disparity was found in samples with nega-
tive status for either one of the receptors HER2, ER, or
PR (Table 3). Samples harbouring mutations in TP53
were also more likely to have a high degree of disparity
compared to samples with wild type TP53 (Table 3).
To focus on specific genes in considering the allelic
disparity of individual loci, we used only the loci in
which the event was observed in 50 percent or more of
the samples, leaving 176 loci (in 158 unique genes, indi-
cated in Additional file 3, Table S1). Additional file 4,
Table S2 shows loci with high levels of disparity
Figure 3 Frequency of studied SNPs showing high degree of allelic disparity within a given cytoband. Percentage of 13,198 loci
according to cytoband localization.
Table 1 Summary of studied loci and genes
Original data
Chromosome Before Filtering After Filtering
SNPs gene SNPs gene
1 9819 1606 8541 1530
2 8702 1055 7718 1030
3 7207 891 6401 861
4 6000 649 5392 626
5 6329 738 5644 712
6 6579 858 5890 832
7 5581 730 4941 708
8 4891 559 4334 541
9 4480 601 3989 581
10 5240 614 4571 593
11 5928 1050 5310 1000
12 5465 881 4781 847
13 3093 288 2794 285
14 3420 501 3013 481
15 3307 477 2928 463
16 3388 624 2909 586
17 4079 896 3584 858
18 2570 236 2260 234
19 3520 1058 3157 1001
20 3007 477 2572 446
21 1381 218 1267 213
22 1886 358 1629 345
X 3480 598 2648 530
Total 109352 15963 96273 15303
Summary of all studied loci and genes in each chromosome before filtering of
the data as well as the numbers of loci and genes showing disparity in both
minor allele (AA) and major allele (BB) after removing the non-polymorphic or
non-informative loci.
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such as stage, grade, Her2 and TP53 mutation status.
We applied multiple testing corrections. Since the num-
ber of loci was 176 (less than 1000), we summarized p-
values in Additional file 4, Table S2. Several genes have
shown significant association in clinical features: AGA,
BANP, BCOR, CACNB1, CSMD1, CUBN, CXCR4,
DERL2, DNMT3B, EDNRB, EPB41L3, FAM20A,
FLJ31882, FLJ33008, FLJ43339, FLJ45831, GEMIN4,
GGTLA1, GHITM, HNT, HTR3B, IGSF4, KIAA1043,
KLF15, KREMEN1, LOC51255, LOC81691, MGC21654,
MYCBP2, NDST4, NGL-1, NVL, PIK3R5, PPP1R9B,
RTN4IP1, SLC2A9, SLC43A2, SPAG6, ST7, STK32B,
TRPS1, TXNL1 and ZW10. Tumour size is classified
into four sub-categories:T 1( T u m o u ri s2c mo rl e s s
across), T2 (Tumour is more than 2 cm but not more
than 5 cm across), T3 (Tumour is more than 5 cm
across) and T4 (Tumour of any size growing into the
chest wall or skin) [25]; here, T3 and T4 are merged in
one category. We found allelic disparity in these chro-
mosomal loci: 2p11.2, 4p16.2, 4q26, 7q31.2, 10p12.2,
10p13, 11q23.2, 11q25, 13q22.3, 15q26.3 and 17p13.3.
We also analyzed the two subtypes of breast cancer,
luminal epithelial-like subtype A and basal epithelial-like
subtype [26] and we found evidence for allelic disparity
in the following chromosomal loci: 8q24.13, 13q22.3,
17p12, 17p13.2, 1q42.12, 17q25.1, 22q11.23, 15q15.1 and
16p12.3. The corresponding genes are given in Addi-
tional file 4, Table S2.
Allelic disparity and pathway analysis
In the list of 176 loci that show a high level of allelic dis-
parity, we used IPA to perform a core analysis of the
gene set and identify the most significantly associated
canonical pathways (CP) as well as over-represented net-
works (Table 4). The top bio functions in IPA are shown
in Figure 6. Table 4 illustrates the top three network
functions, related bio functions, IPA-score, p-values, and
number of molecules for 1) lipid metabolism, small mole-
cule biochemistry, etc. (IPA-score 158); 2) genetic disor-
der, lipid metabolism, etc. (IPA-score = 52); 3) cell death,
cellular development, etc. (IPA-score = 24).
Allelic disparity and stem cell genes
An overview of the gene sets used in this study is given
in Additional file 5, Figure S3. For each gene set, we
Table 2 Cytoband SNP distribution of allelic disparity
Chr Cytogenetic
Band
Average of
Score
Number
of
SNPs in
cytoband
# of snps
with
allelic
disparity
(n = 13198)
Represented genes with disparity
11 11p11.11 100,0 1 1 OR4C46
12 12q11 85,7 1 1 CPNE8
15 15q22.32 77,5 3 2 SMAD6
2 2p15 91,2 85 36 CCT4,COMMD1,KIAA1841,LOC51057,MDH1,TMEM17,UGP2,USP34,XPO1
12 12q21.32 90,8 29 11 Cep290,FLJ35821,HGNT-IV-H,KITLG
3 3q12.2 90,4 50 18 ABI3BP,GPR128,IMPG2,NIT2,TFG,TOMM70A
3 3p11.1 89,5 42 15 CGGBP1,EPHA3,HTR1F,MGC26717,ZNF654
5 5q11.1 86,6 31 11 EMB,PARP8
3 3q13.13 89,6 108 37 CD96,DPPA2,DPPA4,DZIP3,ESRRBL1,GUCA1C,HHLA2,KIAA1524, MORC,PVRL3,TCRIM
9 9p13.1 83,3 3 1 FLJ35740
3 3q13.11 90,6 72 23 ALCAM,CBLB,LOC131368
2 2q33.2 84,8 38 12 ABI2,ALS2CR13,ALS2CR14,ALS2CR16,CD28,CYP20A1,ICOS,RAPH1
6 6q14.2 85,7 19 6 SNAP91,PGM3,KIAA1117,PRSS35,NCB5OR
3 3q12.3 92,2 67 21 FAM55C,IMPG2,LOC131368,NFKBIZ,PCNP,RPL24,SENP7
10 10p11.22 91,6 97 30 ARHGAP12,C10orf68,CCDC7,EPC1,ITGB1,KIF5B,NRP1,PARD3,TCF8
19 19p12 88,1 81 25 LOC148213,LOC163223,LOC91120,ZNF100,ZNF15L1,ZNF208,ZNF254, ZNF429,ZNF43,
ZNF430, ZNF91
3 3p11.2 88,2 13 4 DKFZP564O123,HTR1F
12 12p12.2 89,4 36 11 PDE3A,SLCO1B1,SLCO1B3,SLCO1C1
2 2p12 88,2 181 55 C2orf3,CTNNA2,FLJ13391,HK2,LRRTM1,LRRTM4,MRPL19,PAP,POLE4, REG-III,SUCLG1,TACR1
4 4q13.2 87,5 100 30 BRDG1,CENPC1,DESC1,DKFZp686L1818,EPHA5,FLJ10808,FLJ16046, FLJ21934,GNRHR,HAT,
LOC339967,UGT2B10,UGT2B4,UGT2B7,YT521
14 14q21.2 93,8 70 21 BTBD5,C14orf106,C14orf155,FKBP3,KIAA0423,LRFN5,PRPF39,RPL10L
Chromosomal regions with a high degree of disparity per cytoband (S ≥ 75 )
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Figure 4 Three SNPs with high levels of allelic disparity. Panel (A) illustrates the B allele frequency for rs325349 in blood for all samples (A =
99, AG = 12 and G = 1) on chromosome 5 located in CDH9. Out of the 12 samples scored as AG in the blood, Panel (B). Black dash lines show
the arbitrary thresholds for AA (major allele, A), AB (AG) and BB (minor allele, G) regions, and red dash lines are the real thresholds of
heterozygous. Only one sample is left; 91.7 percent (n = 11) of heterozygous samples show disparity in tumour and all shifted toward major
allele (A). Panel (C) shows the same information for SNP, rs543304 on chromosome 13 located in BRCA2 for blood (A = 70, AG = 34, and G = 8),
and panel (D) shows this information for tumour; 81.8 percent of heterozygous samples (n = 8) shifted toward minor allele (G). Panel (E) shows
B-allele frequency for rs4241189 on chromosome 2 in HECW2 gene, and panel (F) shows that for tumour.
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Page 8 of 13extracted the reported genes and compiled then into
one stem cell gene list. After removing overlapping
redundant information, this list contained 2899 genes.
We then applied a standard chi-square test to compare
the observed level of allelic disparity between the stem
cell gene list and the list of non-stem cell genes (n =
13,198), as well as the levels of amplification and dele-
tion. Genes were scored as disparity genes if more than
50% of loci related to a given gene showed disparity
(score ≥75) (genes w here t he SNPs were e qual ly dis-
tributed were not included, Table 5A). We did not see a
significantly higher level of disparity overall in loci asso-
ciated with the stem cell genes compared to the non-
stem cell genes when “collapsed” by associated or closest
gene (p-value = 0.8008). We also analysed overall copy
number changes between the two gene-sets (stem cell
and non-stem cell) and observed that the stem cell
genes are more often altered by deletion than by ampli-
fication compared to the non-stem cell genes (p-value =
5.41E-04, Table 5B).
Discussion
Chromosomal regions enriched for allelic disparity
We first identified chromosomal regions which were
enriched for allelic disparity. Several of these loci have
been previously reported in association with breast can-
cer. For instance, the genetic variation in 5q11.1 has
previously been associated with the risk of breast cancer
in multiple GWAS studies [27]. Bergamschi et al.
reported 5q11.1 to be more frequently deleted in basal-
like subtype tumours [28]. In the same study, they also
found 3q12.2 loss to be associated with Luminal B
tumours [28,11]. Chromosomal aberrations of 3q13.13
have been detected in several types of cancer, including
Table 3 Clinical features
Grade
Status Grade I Grade II Grade III
Disparity (96273 loci) 79120 (5.9%) 485506 (9.3%) 494383 (12.6%)
No Disparity (96273 loci) 1268281 (94.1%) 4711144 (90.7%) 3451422 (87.4%)
Total 1347401 (100%) 5196650 (100%) 3945805 (100%)
p-value < 0.001, (Cochran-Armitage trend test = X-squared = 68885.98, df = 1)
ER
Status ER = neg ER = pos
Disparity (96273 loci) 471696 (11.7%) 611716 (9.3%)
No Disparity(96273 loci) 3570454 (88.3%) 5932211 (90.7%)
Total 4042150 (100%) 6543927 (100%)
p-value < 0.001, (Pearson’s Chi-squared test, X-squared = 14659.47, df = 1)
HER2
Status HER2 = neg HER2 = pos
Disparity (96273 loci) 820891 (10.4%) 191389 (9.9%)
No Disparity(96273 loci) 7070289 (89.6%) 1733669 (90.1%)
Total 7891180 (100%) 1925058 (100%)
p-value < 0.001, (Pearson’s Chi-squared test, X-squared = 14659.47, df = 1)
TP53
Status TP53 = wildtype TP53 = mutate
Disparity (96273 loci) 607219 (8.2%) 483065 (14.3%)
No Disparity(96273 loci) 6802862 (91.8%) 2885412 (85.7%)
total 7410081 (100%) 3368477 (100%)
p-value < 0.001, (Pearson’s Chi-squared test, X-squared = 96216.44, df = 1)
PR
Status PR = neg PR = pos
Disparity (96273 loci) 659139 (12%) 409458 (8.2%)
No Disparity(96273 loci) 4826429 (88%) 4594835 (91.8%)
Total 5485568 (100%) 5004293 (100%)
p-value < 0.001, (Pearson’s Chi-squared test, X-squared = 42038.96, df = 1)
Distribution of the samples according to the clinical features such as grade, tumour size, ER, PR, HER2 status, breast cancer subtypes, and TP53 mutation status
between the SNPs showing disparity and those not showing disparity.
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Page 9 of 13breast, gastric, colon, and squamous cell carcinomas of
head and neck; furthermore, KIAA1524 residing in this
region has been associated with an aggressive form of
breast cancer [29].
Single-SNP allelic disparity
Next, we further identified the SNPs that most strongly
contributed to allelic disparity. Such SNPs were, for
instance, SNP rs543304 located in BRCA2, rs325349
located in CDH9, and rs4241189 located in HECW2.
Abnormalities or mutations of BRCA2 gene have been
linked to increased risk of both familial breast and ovar-
ian cancer [29]. The encoded protein is involved in
repairing cell damage and maintaining normal growth of
breast cells [29]. CDH9 encodes a type II classical cad-
herin from the cadherin family. The cadherins are inte-
gral membrane proteins important for cell-cell adhesion
[30]. HECW2 encodes an E3 ubiquitin-protein ligase
and mediates ubiquitination of TP73, a p53 family mem-
ber regulating cell growth and apoptosis. The enzyme
acts to stabilize TP73 and enhance activation of tran-
scription by TP73 [31].
Figure 5 Allelic disparity in relation to clinical parameters. Trend of disparity in each individual locus related to the clinical parameter of
grade.
Table 4 Top associated network functions and bio functions
Associated Network Functions Score
Lipid Metabolism, Small Molecule Biochemistry, Nervous System Development and Function 158
Genetic Disorder, Lipid Metabolism, Ophthalmic Disease 52
Cell Death, Cellular Development, Renal Regeneration 24
Disease and Disorders P-Value # Molecules
Genetic Disorder 3.35E-07 - 4.97E-02 96
Inflammatory Disease 8.40E-07 - 4.59E-02 57
Immunological Disease 1.47E-06 - 4.16E-02 51
Connective Tissue Disorders 1.57E-06 - 4.16E-02 40
Skeletal and Muscular Disorders 1.57E-06 - 4.59E-02 55
Molecular and Cellular Functions P-Value # Molecules
Cell Signaling 9.30E-05 - 4.35E-02 17
Molecular Transport 9.30E-05 - 4.91E-02 24
Vitamin and Mineral Metabolism 9.30E-05 - 4.32E-02 15
Lipid Metabolism 1.59E-04 - 4.97E-02 8
Small Molecule Biochemistry 1.59E-04 - 4.97E-02 19
Top three associated network functions and related scores from IPA. Top bio functions contain 1) diseases and disorders, 2) molecular and cellular functions.
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Page 10 of 13Allelic disparity in relation to clinical parameters
Allelic disparity was observed in association to grade
(degree of differentiation), HER2, ER, PR and TP53
mutation status in a number of genes.
SNP rs1041242 found associated with stage is located in
the MYCBP2 gene on chromosome 13 (q22.3). MYCBP2
is known as a probable E3 ubiquitin-protein ligase which
mediates ubiquitination and subsequent proteasomal
degradation of target proteins. MYCBP2 may function as a
facilitator or regulator of transcriptional activation by
MYC [29]. Three SNPs in the gene ST7 on the 7q31.1-
q31.2 region were also found associated with stage. ST7
has been reported as a tumour-suppressor gene involved
in a variety of other human cancers and cell lines derived
from breast tumours have been shown to harbor muta-
tions in ST7 [32]. Locus rs3824271 found associated with
ER status is located in the CSMD1 gene on chromosome
8p23.2, a region reported to be deleted in up to 50% of
breast cancers [33]. Deletion of 8p23.2 has been associated
with high histologic grade [34].
Biological pathway analysis (IPA)
The main network functions identified through pathway
analysis were lipid metabolism, small molecule biochem-
istry, genetic disorder, lipid metabolism, cell death, and
cellular development. Activation of lipid metabolism has
been reported to be an early event in carcinogenesis [35]
and many studies at the single-gene level of lipid metabo-
lism have revealed an effect on tumour genesis [36].
Stem cells
One of the most important characteristics of an embryonic
stem cell is its ability of self-regeneration and differentia-
tion. If one assumes that the initial targets of deregulation
will be among the stem cell genes, then one may expect
that they will represent the “oldest” events in an unstable
genome, which would be reinforced in every cell division.
We therefore hypothesized that the stem cell genes were
likely to have a higher level of disparity in the tumour
[37,38]. To test this, we extracted the stem cell genes from
13 published gene sets [39-41]. This hypothesis, however,
was not confirmed, suggesting that the observed allelic dis-
parity is perhaps not merely a function of the number of
divisions after a single event but the result of a more com-
plex and subtle evolutionary process.
Conclusion
Breast cancer is one the most frequent malignant and a
multifactorial disease affecting women, and thus it is
Figure 6 Bio-functions analysis identified 17 bio-functions as significantly enriched within the genes with a high level of disparity
(Score ≥75). Top bio functions in Ingenuity Pathway Analysis (IPA).
Table 5 Chi-square test results for stem cell
A. allelic Disparity - Score 75
Gene level
Non-Stem Cell genes Stem Cell genes P-value
No Disparity 11315 (95%) 2514 (95%) 0.8008
Disparity 615 (5%) 140 (5%)
Total 11930 (100%) 2654 (100%)
B. Amplification and Deletion
Gene level
Non-Stem Cell genes Stem Cell genes P-value
Amplification 5594 (51%) 1159 (47%) 0.000541
Deletion 5432 (49%) 1313 (53%)
Total 11026 (100%) 2472 (100%)
A 2x2 table showing observed results from the allelic disparity (A) and
amplification or deletion (B) gene lists.
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Page 11 of 13reasonable to hypothesize that there is an association
between multiple genomic rearrangements and tumour
sample disparities. Since most tumours diverge from the
diploid level, many studies have reported only gains and
losses by array CGH.
Our data suggest that directional loss and amplifica-
tion exist in breast cancer. These are highly associated
with grade, which may indicate that they are enforced
with increasing number of cell divisions. Whether there
is a selective pressure for some loci to be preferentially
amplified or deleted remains to be confirmed.
Additional material
Additional file 1: Figure S1 - Flowchart of methods. Two outputs of
Illumina BeadStudio, B allele frequency (BAF on × axis) and Log R ratio
(LRR on y axis) were used as input. A threshold was applied to BAF of
blood to cover the three canonical AA, AB and BB genotypes. If the
number of samples in each region was equal to 112, then SNP was
removed as non-informative data. Both informative blood and tumour
data were retrieved as Blood’ & Tumour’. Mean standard deviation and
variances of Blood’ heterozygous were obtained. Then movement of
Tumour’ samples was compared to that of the Blood’ heterozygous
samples, and if the measured distance was equal to or greater than µBi
±2 sBi, the frequencies of samples moved toward AA/BB regions were
measured. A flexible score (S) was calculated and the symmetrical
regions were eliminated. Involved genes (84881 SNPS) of the asymmetric
region were extracted. The Hardy-Weinberg equilibrium (HWE), the chi-
square test with one degree of freedom, and 5% significance levels of
values were calculated. Those SNPs in the HWE region were flagged. For
the horizontal disparity, among 84,881 SNPs we selected SNPs with a
score of 75 or more (n = 13198). From this list we selected SNPs if 50%
or more of the samples of heterozygote blood shifted (n = 176 SNPs,
representing 158 genes).
Additional file 2: Figure S2 - Disparity of SNPs with score ≥ 75 in
chromosomes 1-23. Disparity of loci with scores greater than or equal
to 75. Blue colour shows SNPs that shifted toward minor allele (AA), and
red colour shows SNPs that shifted toward major allele (BB).
Additional file 3: Table S1 - Loci with highest level of allelic
disparity. This supplementary table contains 13,198 loci that show allelic
disparity. The column of “SNP information” includes loci, gene,
chromosome, cytogenetic band, stem cells and top 176 loci
distinguished by IPA. The columns for “Blood” show the numbers of
major allele (BB), heterozygous, minor allele (AA), percentage of
heterozygous, total number of samples, minor allele frequency (MAF),
and results of HWE chi-square test. The column of “Tumour” contains
percentage of heterozygous with disparity obtained by eq. (4), percent of
allele-specific disparity by eq. (5), preferential allele, score, number of
samples shifted toward major allele and its percentage by eq. (3), and
number of samples shifted toward minor allele and its percentage by eq.
(2).
Additional file 4: Table S2 - Significant loci related to the clinical
features with highest level of allelic disparity. Allelic disparity of
individual loci in relation to clinical parameters such as tumour size, ER,
PR, TP53 mutation, HER2 status, Basal-Lum A subtypes, grade, and lymph
node status was analyzed.
Additional file 5: Figure S3 - Overview of stem cell gene sets.
Thirteen gene sets of stem cells are compiled in one list and compared
for allelic disparity and amplification or deletion.
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